Latest information on COVID-19
Support teaching, research, and patient care.
Dr. Singh is Associate Professor of Psychiatry and Behavioral Sciences and leads a multidisciplinary team that aims to test and innovate novel diagnostic and treatment approaches in youth with a spectrum of mood disorders along a developmental continuum. Her research focuses on investigating the origins and pathways for developing mood disorders during childhood, as well as methods to protect and preserve function before and after the onset of early mood problems. Dr. Singh’s research team in the Pediatric Emotion And Resilience Lab conducts research examining the neural, cognitive, and genetic underpinnings of pediatric mood disorders. She has extensive experience with multi-level investigations involving children and families, as well as clinical, neuroimaging, and dimensionally-based behavioral research assessments. She completed her NIMH career development award that characterizes emotion regulation in healthy offspring of parents with bipolar disorder, and has been leading three independent NIMH funded studies examining the mechanisms of mood and other psychiatric disorders and their treatments among youth. She is extensively involved in collaborations aimed to investigate methods of treating problems associated with and leading up to mood disorders in youth. Specifically, she is examining the benefits of family focused psychotherapy, mindfulness meditation, and medications in youth with or at risk for mood disorders to reduce mood symptoms and family stress. She has also been reviewing the neural effects of medication and psychotherapy in youth. These areas of research aspire to impact our understanding of the core mechanisms and early interventions for pediatric onset mood disorders.
Depression and obesity are reaching epidemic proportions in American youth today, and when they co-occur, they may have compounding deleterious effects, including the development of impaired insulin sensitivity toward insulin resistance (a precursor to diabetes in which cells fail to respond to the normal actions of the hormone insulin). Traditionally, depression and impaired insulin sensitivity have been compartmentalized as separate emotional and physical health syndromes. However, recent evidence suggests interactions and common neurobehavioral pathways between these syndromes that can lead to worsening depressive symptoms. To date, no study has investigated the underlying mechanisms or risk factors for developing worsening of depressive symptoms in youth with depression and impaired insulin sensitivity. There is a pressing clinical need to better identify which youth with depression and impaired insulin sensitivity are most likely to develop worsening depressive symptoms, as current pharmacological and dietary/lifestyle strategies to overcome the burgeoning threat of lifelong depression and obesity are of limited efficacy, have adverse side effects, and in most cases are not curative. Compelling recent data have shown that depressed youth, independent of changes in weight, have early disruptions of neurobiological systems critical for the response and regulation of reward, most notably in the nucleus accumbens, anterior cingulate cortex, insula, and amygdala neural reward circuit. This Research has implicated involvement of the Approach Motivation construct of the NIMH Research Domain Criteria (RDoC) Positive Valence Systems, which describes fundamental aspects of reward dysfunction when youth with depression engage in unhealthy lifestyle behaviors (e.g. overeating) that place them at high risk for progressively worsening depressive symptoms. This proposal aims to use an RDoC framework in the first prospective study to investigate the mechanisms and risk factors for worsening depressive symptoms that are associated with dysfunctional Approach Motivation in youth with depression and impaired insulin sensitivity. To accomplish these aims, 120 overweight girls and boys (ages 9-15 years) seeking treatment for moderate to severe depressive symptoms, will be assessed at baseline, 6 months, and 24 months with cognitive and behavioral markers of Approach Motivation, serum markers of insulin sensitivity, and clinical markers of depression. Youth will be scanned with multimodal MRI at baseline and at 6 months. We aim to determine whether worsening depressive symptoms in youth with depression and impaired insulin sensitivity is mediated by changes in neural reward circuitry, and to identify clinical, demographic, and familial risk factors for developing worsening depression in these youth. This knowledge will be vitally important to mental health and primary care professionals who have limited empirical evidence on which to base their practice. It also has potential to inform the pathophysiology of other disorders associated with dysfunctional approach motivation and to catalyze the development of novel treatment targets.
The conceptual overview for this study is based on 4 key challenges: (a) family history is the strongest risk factor for developing mood disorders in childhood, including major depressive (MDD) or bipolar (BD) disorder, but the mechanisms underlying this risk are unknown; (b) mood disorders in childhood are complicated by diagnostic confusion, which can lead to improper or delayed treatments; (c) multivariate analyses have been underutilized for differentiating etiological risks of BD from MDD or for predicting outcome, and (d) not all youth of parents with BD or MDD develop symptoms suggesting that some are resilient to developing mood disorders. However, the neurobiological basis of resilience from mood disorders is unknown. This project aims to provide innovative solutions to these challenges by charting the evolution of mood symptoms in youth at risk starting from health in order to understand ideal times and methods for intervention. To accomplish these aims, we are conducting an integrative study of 150 families comprised of fathers, mothers, and gender balanced healthy youth, ages 8-15 years: 50 healthy offspring will be of parents with BD, 50 healthy offspring will be of parents with MDD, and 50 healthy controls will have no family history of psychopathology. After screening for eligibility, youth will complete interviews and questionnaires confirming absence of any symptoms of psychopathology and neurocognitive assessments at baseline; they will also do home collection of diurnal cortisol over 2 days, and then return to the lab for an MRI scan. Youth will return for an 18-month clinical follow-up.
401 Quarry Road, Stanford, CA 94305
Antidepressants are commonly prescribed medications used by American youth today to treat a variety of childhood onset psychiatric disorders. However, serious psychiatric adverse events may also emerge from antidepressant use including irritability, agitation, elevated mood, and other adverse events associated with increased dysfunctional emotional arousal. For some youth, these adverse events lead to the development of lifelong psychopathologies such as bipolar disorder. Importantly, the mechanisms through which antidepressants increase risk for developing these adverse events are largely unknown. Moreover, there is a pressing clinical need to better identify which youth taking antidepressants will develop adverse outcomes. Youth who are highly likely to develop adverse responses to antidepressants are those who are already vulnerable to developing dysfunctional emotional arousal. Compelling data from family studies have shown that youth with a family history of bipolar disorder have high rates of major mood and other disorders of emotional arousal, and demonstrate early disruptions of neurobiological systems critical for the regulation of emotional arousal, most notably in the amygdala and ventrolateral prefrontal cortex (VLPFC) neural circuit. Antidepressants are commonly used to treat dysfunctional emotional arousal in high-risk youth; however, they may also increase and accelerate the onset of mood disorders in some of these youth. Research has implicated involvement of the Arousal construct of the NIMH Research Domain Criteria (RDoC) Arousal and Regulatory Systems, which describes fundamental aspects of emotional dysfunction when youth experience an adverse antidepressant-related psychiatric event. This proposal aims to use an RDoC framework in a randomized trial to investigate the etiological mechanisms and risk factors associated with antidepressant-related dysfunctional emotional arousal in high-risk youth. To accomplish these aims, 150 (75/site) high-risk youth, i.e. having at least one first- or second-degree relative with bipolar I disorder, who have moderate to severe depression or anxiety symptoms, will be randomized to receive double-blind treatment either with psychotherapy plus escitalopram or psychotherapy plus placebo. Prior to randomization, we will collect baseline magnetic resonance imaging (MRI), behavioral, and physiological measures of arousal. After randomization, youth will undergo a second MRI scan at 4 weeks, and then will be clinically assessed for up to 16 weeks to evaluate for changes in arousal. We aim to determine whether antidepressant-related changes in arousal are mediated by changes in amygdala-VLPFC circuitry, and to identify neurobiological risk factors for developing dysfunctional arousal. This knowledge will be vitally important to mental health professionals who have limited empirical evidence on which to base their treatment of youth most vulnerable for emotion dysregulation. It also has potential to inform the pathophysiology of disorders associated with dysfunctional emotional arousal and the development of novel targets for treating this complex problem.
Sex differences in psychiatric disorders are common and occur early in development. The etiologic pathways that lead to sex differences in psychiatric disorders stem from complex interactions among clinical, cognitive, genetic, and neural factors that vary as a function of developmental stage. Past studies have been insufficiently powered in the size of their samples and the number of measures assessed to model these risk factors systematically within or between girls and boys, within or across multiple psychiatric disorders, or across developmental stages. Because of these limitations, we do not have a comprehensive understanding of the neurobiology of sex differences in childhood-onset psychiatric disorders, which has hindered timely diagnosis and treatment. Given that current pharmacological and psychotherapeutic strategies to address the burgeoning threat of lifelong psychiatric disorders are of limited efficacy, have adverse side-effects, and in most cases are not curative, there is a pressing clinical need to identify early risk factors for the development of psychiatric disorders. Compelling recent data in children have implicated anomalies throughout development in neural circuitry that is critical for cognitive processing, most notably in prefrontal, limbic, and striatal neural circuits, that may be transdiagnostic and conditioned on sex. Moreover, advances in genetic pathways associated with key cognitive regulatory functions have been translated into increased characterization of the neurocircuitry that subserves psychiatric disorders. This proposal aims to leverage the large multimodal dataset of the Philadelphia Neurodevelopmental Cohort (PNC) to address the pressing questions of which core risk factors predict specific psychiatric disorders conditioned on sex (i.e., within girls and within boys), which factors explain sexual dimorphism in childhood-onset psychiatric disorders, and when sex differences in psychiatric disorders emerge. To accomplish these aims, we will use state-of-the-art high-dimensional modeling methods to develop a parsimonious risk model that integrates clinical, cognitive, genetic, and neural factors in the PNC database to predict sex differences in childhood-onset psychiatric disorders. We will model clinical, cognitive, and genetic data from a large cohort of almost 10,000 boys and girls who are between the ages of 8-21 years, and neuroimaging data in a subset of ~1,500 youth. The PNC database includes measures of normal and abnormal functioning across a wide age range to enable comparisons of outcomes in psychiatric disorders across age and in developmental subgroups. Understanding how clinical, cognitive, genetic, and neural factors interact in the development of sex differences in psychiatric disorders will provide more precise neurobiologically-informed treatment targets.
Preventing the spread of infection through education
Arthur Davison Hospital
Children across Zambia
Dr. Singh’s research investigates the developmental psychopathology, pathophysiology, and treatment of pediatric mood disorders, as well as methods to protect and preserve function before and after the onset of depression or mania. Using an integration of clinical, neuroimaging, genetic, and neuroendocrine tools, her research aims to explore the complex risk factors associated with the development of serious mood disorders in children and adolescents. Dr. Singh and her collaborators have also been actively exploring pharmacological and psychotherapeutic methods of treating mood symptoms associated with and leading up to these disorders in youth. Through national collaborations, she is examining the benefits of a combination of family focused psychotherapy with medication in youth offspring of parents with bipolar disorder to reduce mood symptoms and family stress. In addition, she and her group have been conducting studies examining the neuroimaging effects pharmacological and psychosocial interventions – specifically exploring whether such interventions can reduce limbic hyperactivity and increase prefrontal cognitive control. These areas of research aspire to advance understanding of the core mechanisms, endophenotypes, and early interventions for pediatric onset mood disorders. Dr. Singh has been awarded several NIMH awards integrating innovative neuroimaging techniques and mechanisms of emotion regulation to understand the neurodevelopmental basis of mood disorders among children.<br/><br/>Among the many honors Dr. Singh has received include the NARSAD Young Investigator Award, the Klingenstein Third Generation Foundation Depression Fellowship, the American Psychiatric Association’s Young Minds in Psychiatry Award, and Michigan State University’s Distinguished Young Alumni Award. She was also selected as the Akiko Yamazaki and Jerry Yang Faculty Scholar in Pediatric Translational Medicine.<br/> <br/>Dr. Singh earned her MD at Michigan State University and her MS at University of Michigan. She completed her combined residency in Pediatrics, Psychiatry, and Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center. After two years of neuroimaging training at the Center for Interdisciplinary Brain Sciences Research at Stanford University, she joined the faculty at Stanford in 2009.
A Study of the Relationship of Psychosocial Function With Mood Symptoms in Offspring of Parents With Bipolar Disorder
The primary purpose of this study is to compare, over 24 months, the time spent with
clinically significant mood symptoms (ie, mania, depression), as measured by the Longitudinal
Interval Follow-Up Evaluation (LIFE) and the Psychiatric Status Rating Scale (PSR), in
offspring of bipolar parents with and without at least mild impairment in psychosocial
Stanford is currently not accepting patients for this trial.
For more information, please contact Spectrum Child Health, 650-724-1175.
View full details
Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth
A 16-week double blind, placebo-controlled investigation of escitalopram in adolescents with
depression and/or anxiety with a family history of Bipolar Disorder. Subjects will be
evaluated using semi-structured diagnostic interviews and symptom ratings, participate in a
MRI scan and then randomized to treatment. Following randomization, high-risk youth will have
visits every week for the first 4 weeks of treatment then biweekly up to 16 weeks during
which time tolerability and ratings will be performed. MRI scan will be repeated at week 4.
Stanford is currently not accepting patients for this trial.
For more information, please contact Manpreet K Singh, MD MS, 650-725-5922.
iTBS in Refractory Pediatric Depression
This work will mark the first step in understanding the neural targets for rTMS in youth with
difficult to treat depressive symptoms, creating benchmarks for optimizing the safety and
efficacy of rTMS for pediatric populations through precision targeting, and encourage funding
applications for larger sham- controlled randomized clinical studies.